Mycobacterium avium subspecies paratuberculosis - any experiences in treatment/eradication?
-
This is a brief shoutout to anyone who has direct or indirect knowledge or experience on successful treatment, i.e. eradication, of Mycobacterium avium subspecies paratuberculosis or MAP as it's often abbreviated as a very particular subspecies among the non-tubercular mycobacteria (NTM).
Please post, especially wrt antibiotic regimens.Obv. a successful treatment differs substantially from a classic Mtb antibiotic cocktail, not least because there's no target for isoniazid in MAP, and also the replication rate is at most half that of Mtb, non-caseating, and it's an obligate intracellular pathogen persisting in vacuoles within immune cells, devoid of cell walls, causing strong inflammation and evading lysosome fusion and immunity and being a detriment to the latter and the body as a whole.
It's existence and activity in man has been sufficiently shown since almost 50 years ago. It's the microbiologically unqualified gastroenterologists and the policy makers (for the usual reasons to the detriment of humankind and avoidance of huge economic implications) to blame for obscuring its recognition.
This is one of the if not the earliest published work on it with electron-microscope proof:
Mycobacteria as a possible cause of inflammatory bowel disease; Burnham et al. 1978 https://pubmed.ncbi.nlm.nih.gov/80630/
well worth reading the full text.
There's not only IBD and Crohn's but also an abnormally huge association with rheuma patients (as in reactivity to MAP proteins) in contrast to control groups been found in recent years.
The original distinction to intestinal TB made by Crohn in the 1930's was the finding o not of acid-fast bacilli in tissue. Yet in contrat to Mtb, MAP has been shown to be present only in it's non-bacillary form.